CTI BioPharma, based in Seattle, WA, is dedicated to developing innovative therapies for patients with rare blood-related cancers. By delving into the scientific roots of these diseases, CTI aims to provide novel treatments that address the underlying drivers of the conditions.
The company's focus on myelofibrosis has led to the approval of pacritinib in the U.S. for adults with specific platelet counts, with ongoing Phase 3 trials like PACIFICA evaluating its efficacy compared to standard therapies. CTI BioPharma's mission is centered on impacting patients' lives by advancing new medicines that offer meaningful benefits in the realm of blood cancer treatment.
Generated from the website